Dr. Alexander A. Boucher, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 27
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MN license 57181
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 27
- Services billed
- 81
- Patients’ average age
- 45
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Minneapolis, MN | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,055 in research payments for these studies, mostly to the institutions running them.
- A phase 3B, prospeca phase 3B, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (RADAMTS-13, also known as bax 930/SHP655) in the prophylactic and on…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.